glp 1 parkinson's disease and neuroprotection Repurposing GLP-1 Receptor Agonists for Disease: Current Evidence Future Opportunities | Pharmaceutical Medicine GLP-1R Agonists - Glucagon-Like Peptide

The UK GLP-1 programme appears to offer a more limited support model focused on workshops, community, and app-based content rather than 1-to-1 clinical coaching

On paper, Bridge is a win

Its often used for: Joint pain and inflammation Ligament sprains and tendon injuries Gut repair (think IBS, ulcers, or leaky gut) Post-surgical healing At VYVE Wellness, we often recommend BPC-157 for clients dealing with nagging injuries, chronic inflammation, or slow tissue recovery

Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8

The quality of research in this area is poor, with no good-quality evidence to back up the benefits touted by proponents